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Summary The expression of epidermal growth factor receptor (EGFR) was studied immunohistochemically
in 234 cases of transitional cell bladder cancer. EGFR was overexpressed in 35% of cases and distinct nuclear
localisation of EGFR positivity was found in 31% of the tumours. Overexpression was related to invasive
growth, grade 2-3 histology, non-papillary type, DNA aneuploidy and high proliferation rate of cancer cells.
The expressions of p53 and EGFR were interrelated, while expression of c-erbB-2 was independent of EGFR
expression. Progression of superficial tumours, recurrence-free survival and survival were independently related
to overexpression of EGFR in multivariate analysis. T category, S-phase fraction and non-papillary type
included all the available prognostic information when the entire cohort was analysed by multivariate
methods. The results show that overexpression of EGFR is related to several malignant features and prognosis
in superficial bladder cancer. Moreover, the results suggest that overexpression of EGFR is usually a late event
in bladder cancer development related to genetic instability rather than an early event in malignant transfor-
mation. Further studies are still needed to establish whether the direct measurement of cell proliferation or
analysis of growth factor receptors and other oncoproteins gives more accurate prognostic information in
bladder cancer.
The prognosis of transitional cell bladder cancer (TCC)
depends on the extent of the primary tumour at diagnosis
(Zingg & Wallace, 1985; Lipponen et al., 1992, 1993) and its
biological characteristics (Neal et al., 1990; Lipponen,
1993a,b; Sarkis et al., 1993). Recent analyses indicate that the
proliferation rate of cancer cells is an important factor when
the metastatic potential of TCC is evaluated. Flow cytomet-
ric S-phase fraction measurements (Lipponen et al., 1993),
mitotic index (Lipponen et al., 1992) and proliferation-
associated proteins (Limas et al., 1993) have uniformly
confirmed the interrelationship between cell proliferation and
prognosis. The proliferation of cancer cells is regulated
through autocrine and paracrine growth factors (Cohen 1983;
Argile's et al., 1992; Coombs et al., 1993; Lipponen, 1993b);
Sauter et al., 1993) and by intrinsic genetic alterations (Lip-
ponen, 1993a; Sarkis et al., 1993). Mutations in the p53 gene
may result in increased cell proliferation and a malignant
phenotype (Lipponen, 1993a; Sarkis et al., 1993). The expres-
sion of c-erbB-2 protein, which is a transmembrane growth
factor receptor (Lofts & Gullick, 1992), has been related to
increased cell proliferation and metastatic potential in TCC
(Moriyama et al., 1991; Lipponen, 1993b) as well as in other
neoplasms (Kallioniemi et al., 1991). The HER/neu-2 gene,
which encodes c-erbB-2 protein, has an outstanding sequence
homology to EGFR, although they are not identical
(Schahter et al., 1985; Yamamoto et al., 1986). The epider-
mal growth factor proto-oncogene is located on chromosome
7pl3 (Rosenkranz et al., 1989) and it encodes EGFR protein
for the cytokines epidermal growth factor (EGF) (Adamson
& Rees, 1981) and transforming growth factor a (TGF-x)
(Massague, 1983). Expression of EGFR has been related to
increased cellular proliferation (Argile's et al., 1992; Gas-
parini et al., 1992; Engebraaten et al., 1993; Sauter et al.,
1993). The present analysis was done to assess the prognostic
value of EGFR expression in relation to other indicators of
cell proliferation in a cohort of 234 bladder cancer patients
with a long follow-up.
Patients and methods
Patients
A total of 234 patients with TCC were followed up for a
mean (s.e.) of 11.3 (0.3) years (range 3.2-25.2 years) during
1965-91. There were 193 males and 41 females and their
mean (s.e.) age was 67.2 (0.6) years (range 33.1-85.0 years)
at the time ofdiagnosis. The diagnosis, treatment and follow-
up of patients was conducted according to standard clinical
practice (Zinng & Wallace, 1985). Superficial tumours were
treated by transurethral resections and adjuvant intravesical
chemotherapy, and muscle-invasive tumours were treated by
cystectomy, cystectomy and radiation therapy or radio-
therapy alone (Table I). The clinical staging of tumours was
done according to UICC (1978). Progression of tumours was
defined as an increase in T (not Ta/Tl), N and M categories
during the follow-up. The causes of death were verified from
patient files, autopsy reports and from the files of Finnish
Cancer Registry. Seventy-nine patients died of bladder cancer
and 76 from other diseases during the follow-up period.
Histological methods
The transurethral or preoperative biopsy specimens from the
primary tumours were fixed immediately after removal in
buffered formalin (pH 7.0) and embedded in paraffin. For
histological grading (Mostofi et al., 1973) 5fLm sections were
Table I The treatment of patients in various stage groups
Type of therapy Ta-NTJ T2 T3 T4
No therapy - - - 3
Electrocoagulation and 141 64 18 7
transurethral resection
Partial cystectomy 8 9 5 -
Total cystectomy 6 15 8 -
Cystecomy and radiation 3 8 14 4
Radiation 7 4 9 11
Intravesical chemotherapy 29 14 1 -
Note that the same patient may have received several types of
therapy during the follow-up.
Correspondence: P. Lipponen.
Received 8 September 1993; and in revised form 25 January
1994.
(D Macmillan Press Ltd., 1994 Br. J. Cancer (1994), 69, 1120-1125EPIDERMAL GROWTH FACTOR RECEPTOR IN BLADDER CANCER 1121
cut and stained with haematoxylin and eosin. The growth
type of tumours was identified, and they were divided into
papillary and non-papillary types. The methods and results
of flow cytometry (Lipponen et al., 1993) and morphometry
(Lipponen et al., 1992) have been detailed elsewhere. In brief,
paraffin-embedded material was used in flow cytometry
(FCM) and the S-phase fraction was calculated by using the
rectilinear method. Tumours with a DNA index < 1.00 were
considered diploid, and tumours with a DNA index > 1.00
were aneuploid. For morphometry, the IBAS 1 and 2 image
analysis system was used and the nuclei were traced by using
a mouse connected to a computer which automatically cal-
culated the nuclear parameters. In this analysis mean nuclear
area, s.d. of nuclear area, nuclear perimetry, s.d. of
perimetry, shortest nuclear axis and longest nuclear axis were
used (Lipponen et al., 1992).
The p53 immunohistochemistry (Novocastra Laboratories,
Newcastle Upon Tyne, UK; CM1 antibody) (Lipponen,
1993a) and c-erbB-2 immunohistochemistry (Novocastra
Laboratories; Newcastle Upon Tyne, UK, NCL-CB 1I
antibody) (Lipponen, 1993b) were performed according to
routine protocol (see EGFR immunohistochemistry) and
have been described in detail elsewhere.
EGFR immunohistochemistry
For immunohistochemical demonstration of EGFR protein,
5 tm sections from the primary TCCs were deparaffinised
and washed for 5 min with phosphate-buffered saline (PBS).
The slides were covered with 3% normal horse serum in PBS
for 15 min and then incubated overnight at +4°C with
EGFR monoclonal (Parker et al., 1984) antibody (Cam-
bridge Research Biochemicals, Valleystream, NY; Cat.
No. OM-1 1-951) diluted at 1:2,000. Sections were washed
twice for 5 min with PBS, then incubated for 20 min with
horse anti-mouse biotinylated secondary antibody (Vector,
CA, USA) diluted 1:200 in PBS. Slides were washed twice in
PBS for 10 min and incubated for 20 min in preformed
avidin-biotin-peroxidase complex (ABC, Vectastain Elite
kit, Vector). Sections were washed twice for 5 min with PBS,
then developed with diaminobenzidine tetrahydrochloride
substrate (Sigma, UK), counterstained with Mayer's
haematoxylin, dehydrated, cleared and mounted. Squamous
cell carcinomas from oral cavity and human placenta were
used as positive controls, and they were positive in all of the
experiments. Sections from the same tumours prepared with-
out primary antibody were used as negative controls and
were negative in all of the experiments. Since some of the
tumours showed distinct nuclear staining, additional
experiments were done to exclude non-specific nuclear locali-
sation of immunopositivity. The same staining procedures
were done by using an irrelevant antibody of the same
isotype (E-cadherin, Novocastra Laboratories) diluted at
1:10 in PBS, and no nuclear reactivity was found (six sec-
tions from tumours with distinct nuclear staining). Secondly,
in dilution experiments (four tumours with simultaneous
membrane, cytoplasmic and nuclear positivity for EGFR)
with the primary antibody, the staining was simultaneously
reduced in all three cellular compartments as the dilution of
the primary antibody was increased from 1:2,000 to 1:4,000,
1:6,000, 1:8,000, 1:16,000 and to 1:32,000. The sections
showed no positive staining at the dilution of 1:32,000.
Scoring ofEGFR expression
The intensity of staining was graded subjectively into four
categories by light microscopy: negative (0), weakly positive
(1), equal to placenta (2) and stronger than placental control
(3). The entire section was screened and the scoring was
based on the findings in tumour areas with the strongest
positivity for EGFR. The sections which showed weaker or
equal positivity to human placenta were considered negative,
and all those sections that showed stronger staining than
human placenta were considered EGFR positive in the final
analysis. This classification was adopted since it gave the best
prognostic results (other group limits were also tested) and
the differences in biological variables between the grades 0
and 2 were not significant. The scoring was based on the
evaluation of the cytoplasmic and membrane staining
together. Since some tumours showed distinct nuclear stain-
ing, the fraction of positively staining nuclei was scored in
the entire section. In the analysis of results the fraction of
positive nuclei was classified into three categories: negative,
1-10% positive nuclei and over 10% positive nuclei.
Scoring ofc-erbB-2 andp53 protein expression
The scoring of c-erbB-2 as well p53 has been reported in
detail previously. In brief, c-erbB-2 expression was cate-
gorised into four grades: negative, weak, moderate and
intense (Lipponen, 1993b). Expression of p53 (fraction of
positive nuclei) was categorised in this analysis as follows:
negative, 1-20% positive nuclei and over 20% positive
nuclei (Lipponen, 1993a).
Statistical methods
The differences between the groups were tested using stan-
dard statistical tests, which are indicated along with the
results when appropriate. Univariate survival analysis was
based on life table (log-rank analysis) method with the stati-
stics by Lee and Desu (1972). Recurrence-free survival was
defined as the time elapsed between the primary therapy and
the first recurrent tumour in the bladder. Multivariate sur-
vival analysis (Cox, 1972) was done with the BMDP (2L) in
a stepwise manner using the deaths due to bladder cancer as




According to the EGFR scoring system used 35/234 (15%) of
the tumours were negative, 76/234 (32%) were weakly
positive, 41/234 (17%) showed similar staining to human
placenta and in 82/234 (35%) of cases EGFR was overex-
pressed. The positivity was located at cell membranes and in
cytoplasm, albeit the membranous staining predominated in
the majority of cases (Figure la). The expression of EGFR
showed marked intratumoral variation (Figure lb), while the
invasive carcinoma cells were usually positive for EGFR. In
weakly staining cases basal cells were often positive for
EGFR. In 74/234 (31%) cases nuclear staining showed
immunoreactivity (Table II). Nuclear staining was seen also
in cases in which the membrane staining was weak or even
absent (Figure lc) and cytoplasmic and membrane staining
and nuclear staining were not interrelated (chi-square,
P=0.5).
EGFR expression related to standardprognosticfactors
Thirty-nine per cent of muscle-invasive tumours were positive
for EGFR, while 81% of superficial tumours were negative
(Table III). The involvement of the pelvic lymph nodes
(P = 0.28) or distant metastasis (P = 0.21) at diagnosis could
not be related to EGFR overexpression.
Non-papillary tumours were more often positive for
EGFR than the papillary ones (Table III). Similarly, 49% of
the grade 3 tumours showed overexpression of EGFR, in
contrast to 30% of grade 1 tumours (Table III). DNA
aneuploidy was significantly related to EGFR overexpression
(Table III), and tumours with a high proliferation rate were
also positive for EGFR. The mean (s.e.) S-phase fraction
(SPF) in EGFR-negative tumours was 8.8% (0.8%), in con-
trast to 13.1% (1.5%) in EGFR-positive ones (t-test,
P= 0.015). The mitotic index per mm2 of neoplastic
epithelium was 11.7 (1.1) and 15.1 (1.6) respectively (t-test,
P= 0.082). The morphometrically measured mean nuclear1122 P. LIPPONEN & M. ESKELINEN
a area and the s.d. of nuclear area were independent of EGFR
overexpression.
Nuclear expression of EGFR was related significantly to
grade, mitotic frequency, morphometrically measured nuclear
area, s.d. of nuclear area and expression of p53 (Table II).
Nuclear expression of EGFR was independent of TNM clas-
+ sification (chi-square, P = 0.3-0.9), papillary status (chi-
square, P = 0.14) and DNA ploidy (chi-square, P= 0.7).
Interrelationship betweenp53, c-erbB-2 and EGFR
The overexpression of p53 showed a statistically significant
association with overexpression of EGFR, as shown in Table
IV. Overexpression of c-erbB-2 and EGFR were not signifi-
cantly interrelated (Table IV). The relationship was also
similar in a separate analysis of superficial tumours alone.
EGFR overexpression andprognosis
P Progression of superficial tumours was related significantly to
EGFR overexpression, as shown in Table V. In a logistic
multivariate regression analysis (progression/no progression)
'W". (DNA ploidy, SPF, grade, papillary status, nuclear area, s.d.
of nuclear area, nuclear perimetry, s.d. of nuclear perimetry,
shortest nuclear axis, longest nuclear axis, p53, c-erbB-2,
b EGFR), SPF [P(s.e.) = 0.12 (0.04), P = 0.0039] and overexp-
ression of EGFR [P(s.e.) = 1.50 (0.67), P = 0.0268] predicted
progression independently of T category. Also, in the entire
cohort progression in T category (chi-square, P = 0.00021),
N category (chi-square, P<0.0001) and M category (chi-
square, P<0.0001) was related to EGFR overexpression.
The recurrence-free survival and survival of superficial
tumours were not significantly related to EGFR overexpres-
sion (X2 = 2.3, P = 0.126, and X2 = 0.6, P = 0.4, respectively).
In T2-T3 tumours overexpression of EGFR showed a non-
significant association with prognosis (2= 2.59 P = 0.113).
The survival analysis of the entire cohort showed that EGFR
overexpression is related to unfavourable outcome during a
long-term follow-up (Figure 2). In superficial tumours
nuclear positivity predicted progression in T category
(%2= 6.3, P= 0.41), in N category (X2=4.5, P= 0.1) and in
M category (X2 = 5.2, P=0.07), while in survival analysis
nuclear expression had no significant prognostic value.
In Cox's analysis mean nuclear area [p (s.e.) = 0.036
(0.017), P = 0.010, RR (risk ratio) = 1.03], SPF [1
(s.e.) = 0.086 (0.035), P= 0.056, RR = 1.09] and overexpres-
sion of EGFR [p (s.e.) = 1.345 (0.685), P = 0.052, RR = 3.83]
were independent predictors of survival in Ta-TI tumours.
Recurrence-free survival was independently predicted by
overexpression of EGFR [p (s.e.) = 0.617 (0.281), P = 0.018,
RR = 1.85]. The use of intravesical chemotherapy was also
C considered in the analysis, but it had no independent
prognostic value over biological variables. In the entire
cohort survival was independently related to T category
[1 (s.e.) = 0.926 (0.149), P<0.001, RR = 2.52], SPF
[1 (s.e.) = 0.042 (0.014), P = 0.001, RR = 1.04] and papillary
status [p (s.e.)= -0.607 (0.314), P = 0.061, RR= 0.54]. A
separate analysis of T2-T3 tumours showed no independent
prognostic value for EGFR overexpression.
Discussion
Wq c-erbB-2 and EGF (Schahter et al., 1985; Yamamoto et al.,
1986; Asamoto et al., 1990; Coombs et al., 1991; Moriyama
Figure 1 a, The expression of EGFR protein is intense at the
cell membranes and in the cytoplasm. Magnification x 320. b,
The expression of EGFR may show marked intratumour and
intercellular variation. Magnification x 320. c, The expression of
EGFR oncoprotein is intense in the nucleus while the cytoplasm
and cell membranes are only weakly positive. Magnification
x 320.EPIDERMAL GROWTH FACTOR RECEPTOR IN BLADDER CANCER 1123
Table II The relationship between nuclear expression of EGFR, grade, mitotic index,
s.d. of nuclear area and p53
Nuclear positivity for EGFR
Variable Number 0% 1-10% > 10% Statistics
Grade 1 90 71 (79%) 15 (17%) 2 (2%)
Grade 2 95 57 (60%) 32 (33%) 6 (6%) x2= 13.4
Grade 3 49 30 (61%) 13 (26%) 6 (12%) P =0.0094
M/V 8mmM2 112 87 (78%) 21 (19%) 4 (3%) x2=9.3
M/V>8mm-2 122 71 (58%) 39 (32%) 10 (8%) P =0.0094
SDNA 25 lm-2 150 109 (72%) 38 (25%) 4 (3%) x2=9.3
SDNA 25 sm2 84 49 (58%) 22 (26%) 10 (12%) P =0.0095
p53 (+) 0% 125 92 (74%) 26 (21%) 7 (6%)
p53 (+) 1-20% 23 11 (45%) 11 (50%) 1 (5%) X2= 13.0
p53 (+) >20% 34 17 (50%) 13 (38%) 4 (11%) P =0.0123
Chi-square test; p53 was not available in all cases. M/V = volume-corrected mitotic
index. SDNA = standard deviation of nuclear area.
Table III The cases subdivided according to EGFR expression, T category, papillary
status, WHO grade, DNA ploidy and S-phase fraction (SPF)
Variable Number EGFR negative EGFR positive Statistics
Ta 42 34 (81%) 8 (19%)
TI 68 50 (73%) 18 (27%) x2= 13.5
T2 64 36 (56%) 28 (44%) P = 0.0089
T3 37 18 (49%) 19 (51%)
T4 23 14 (61%) 9 (39%)
Grade 1 90 63 (70%) 27 (30%)
Grade 2 95 64 (67%) 31 (33%) x2= 5.4
Grade 3 49 25 (51%) 24 (49%) P =0.0662
Non-papillary 39 17 (43%) 22 (57%) x2= 9.3
Papillary 195 135 (69%) 60 (31%) P =0.0021
Diploid 111 84 (76%) 27 (34%) x2= 12.5
Aneuploid 89 46 (52%) 43 (48%) P = 0.0004
SPF < 10% 108 80 (74%) 28 (26%) X2= 5.8
SPF >10% 64 36 (56%) 28 (44%) P =0.0159
Chi-square test; DNA ploidy and SPF were not available in all cases.
Table IV The interrelationship between expression of EGFR, p53 and c-erbB-2
Number EGFR negative EGFR positive Statistics
p53 (+) 0% 125 90 (72%) 35 (28%)
p53 (+) 0-20% 23 14 (56%) 9 (36%) x2=9.4
p53 (+) >20% 34 15 (44%) 19 (56%) P=0.0090
c-erbB-2 (0) 130 87 (67%) 43 (33%)
c-erbB-2 (1) 65 40 (61%) 25 (38%) x2=0.7
c-erbB-2 (2, 3) 29 18 (62%) 11(38%) P = 0.6
Chi-square test; p53 and c-erbB-2 were not available in all cases.
Table V The progression of superficial tumours related to EGFR overexpression
Category Number EGFR negative EGFR positive Statistics
T category
No progression 89 73 (82%) 16 (18%) x2 = 8.2
Progression 21 11 (52%) 10 (48%) P = 0.0040
M category
No progression 96 77 (80%) 19 (20%) x2= 6.1
Progression 14 7 (50%) 7 (50%) P = 0.0129
Chi-square test.
et al., 1991; Wright et al., 1991; Lipponen, 1993b; Sauter et
al., 1993) are both related to cancer cell proliferation, high-
grade histology and invasive disease in bladder cancer. The
cellular effects of TGF-x and EGF are mediated through
EGFR (Cohen, 1983; Massaquee, 1983), and the intracellular
component of the EGFR exhibits tyrosine kinase activity,
having binding sites for ATP (Cohen, 1983). This results in
the autophosphorylation of the EGFR and phosphorylation
of several target proteins (Ushiro et al., 1980). Since EGF
and TGF-a are mitogens (Cohen, 1983; Argile's et al., 1992;
Engebraanten et al., 1993), EGFR-positive tumours are
usually rapidly proliferating (Gasparini et al., 1992; Sauter et
al., 1993), which could also be confirmed in this immuno-
cytochemical analysis. Experimental analyses have also
shown that migration and invasive potential may be
modulated through EGFR (Engebraaten et al., 1993), but the
relationship between cell proliferation and EGF function is
not always clear-cut (Argile's et al., 1993). In renal cell
carcinoma cell lines the response of cells to EGF and TGF-x
is dependent on cell status (Argile's et al., 1993).
The fraction of tumours overexpressing EGFR was close
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Figure 2 The survival of patients categorised according to exp-
ression of EGFR. Curve A: EGFR negative (n = 151); curve B:
EGFR positive (n = 83) (X2 = 5.1, P = 0.0238).
Wright et al., 1991). EGFR positivity was related to high
histological grade and invasive disease, which is also in agree-
ment with previous publications (Neal et al., 1990; Wright et
al., 1991). However, in this analysis a higher fraction of
grade 1 tumours showed overexpression of EGFR than in
previous studies. Non-papillary growth architecture was
related to EGFR overexpression, which is in agreement with
the rapid cellular proliferation in non-papillary bladder
tumours (Lipponen et al., 1993).
Our results confirm recent findings by Sauter et al. (1993),
who demonstrated that polysomy and aneuploidy are related
to amplification and overexpression of EGFR in bladder
cancer. Expression of c-erbB-2 and EGFR were independent
characteristics of cancer cells, which supports previous results
(Moriyama et al., 1991; Gullick et al., 1991; Wright et al.,
1991). In contrast, we found a significant relationship
between the overexpression of p53 and EGFR, which is at
variance with the results of Wright et al. (1991). Several
reports have indicated a significant relationship between
c-erbB-2, p53 and increased cell proliferation in neoplastic
diseases (Kallioniemi et al., 1991; Lipponen, 1993a,b;
Haapasalo et al., 1993). Consequently, the relationship
between EGFR and oncoproteins has a logical basis. The
differences in results may be due to different antibodies used,
different numbers of cases analysed and different grade/stage
distributions of tumours. In superficial tumours EGFR, p53
and c-erbB-2 are rarely expressed (Neal et al., 1990; Wright
et al., 1991; Moriyama et al., 1991; Lipponen, 1993a,b;
Sauter et al., 1993) which may lead to variable results when
small numbers of cases are analysed.
The expression of EGFR in cancer cell nuclei has been
recognised previously (Goppinger et al., 1989; Ramael et al.,
1991; Tervahauta et al., 1993), but none of the reports
reviewed this characteristic in bladder cancer cells. The
nuclear expression of EGFR was related to large nuclear size,
large variation in nuclear size and cell proliferation. How-
ever, this feature had no significant prognostic value over
conventional cytoplasmic and membrane expression of
EGFR. The nuclear localisation of EGFR positivity may be
related to the presence of EGFR receptors in the nuclei as
demonstrated in cell cultures (Jiang & Schindler, 1990). The
nuclear localisation of EGFR may be also related to modula-
tion of gene transcription (Rakowicz et al., 1986) or it may
even be related to control of differentiation (Green, 1977).
Nuclear localisation of EGFR positivity with the same
antibody has been related to HPV and CIN lesions in the
uterine cervix, which are accompanied by similar nuclear
changes as in this analysis (nuclear atypia, p53 positivity)
(Goppinger et al., 1989; Tervahauta et al., 1993). According
to previous immunoabsorption studies (datasheet, Cambridge
Research Biochemicals, Valleystream, NY), non-specific
staining is unlikely. Also, our dilution experiments suggest
that the staining is specific.
The results of survival analysis show that overexpression of
EGFR has prognostic significance in transitional cell bladder
cancer as in breast carcinomas (Gasparini et al., 1992). The
present results are in agreement with the results of Neal et al.
(1990), who demonstrated prognostic value for EGFR over-
expression in superficial bladder tumours and in invasive
tumours. Although direct indicators of cell proliferation were
included in this analysis, overexpression of EGFR predicted
independently recurrence-free survival and survival. However,
when the entire series was analysed, standard prognostic
factors included all the available prognostic information.
This is at variance with the results of Neal et al. (1990),
probably because proliferation indicators other than expres-
sion of EGFR were not included in their analysis.
Although the patients were treated in several different
ways, multivariate analysis showed that the prognostic results
in superficial tumours were mainly determined by the intrin-
sic malignant potential of the tumours. Our previous analysis
of tumours treated by cystectomy confirms that the biological
factors are also important determinants of the prognosis in
muscle-invasive tumours (Lipponen, 1992). Accordingly, the
treatment had hardly any significant confounding effect on
the prognostic results based on the biological factors.
The results suggest that overexpression of EGFR may
have a higher prognostic potential than the overexpression of
p53 (Lipponen, 1993a; Sarkis et al., 1993) or c-erbB-2 (Lip-
ponen, 1993b) in bladder cancer since the altered expression
of the latter protein had no independent prognostic value in
this multivariate analysis. The prognostic value of over-
expression of p53 seems to be complicated by antibody for-
mation against mutated p53 protein (Davidoff et al., 1992)
and because of the association of uncontrolled cell prolifera-
tion with specific mutations in the p53 gene (Merlo et al.,
1993). The amplification and overexpression of EGFR, p53
and c-erbB-2 may indicate a general degree of genomic in-
stability since the expression of both of these oncoproteins is
related to advanced disease in bladder cancer. Normal cells
are able to control genomic instability (Tlsty et al., 1992),
and the loss of these control mechanisms may eventually
promote tumour formation.
In summing up the results of the present study and the
previous analyses in bladder cancer it seems reasonable to
suggest that the overexpression of EGFR is related to several
malignant histological features in bladder cancer and parti-
cularly to cell proliferation. It remains to be established
whether the direct measurement of cell proliferation by flow
cytometry or by using proliferation-associated molecules
(Haapasalo et al., 1993; Limas et al., 1993) gives more
accurate prognostic estimates in superficial tumours than the
demonstration of EGFR amplification or overexpression
(Sauter et al., 1993). Similar issues must also be considered
when the prognostic potential of other oncoproteins and
growth factors is considered. A study along these lines based
on a prospectively followed up population of bladder cancer
(Ta-TI) patients has already been started in our
laboratory.
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